AB0946 A META-ANALYSIS TO EVALUATE THE EFFICACY AND SAFETY OF IGURATIMOD ON ACTIVITY AX-SPA

Background

Iguratimod is a newly-developed small molecular anti-rheumatic drug, which can inhibit the effects of prostaglandin E2, TNF-α and IL-17. Iguratimod had been reported to be effective in the treatment of SpA. Iguratimod was implied to be of potential efficacy on ax-SpA.

Objectives

This study was aimed to demonstrated the efficacy and safety of Iguratimod on activity ax-SpA (ASDAS>2.1).

Methods

We performed a meta-analysis to systemically evaluate the efficacy and safety of Iguratimod by gathering the published RCTs about the treatment of Iguratimod in ax-SpA, mean differences (MD) and 95% CI of the change of back pain, morning stiffness, PhGA, ASDAS, BASDAI, BASFI and concertation of TNF-α, ESR and CRP were calculated. Besides, the odds ratio (OR) and 95% CI of the ASAS 20, ASAS 40, partial remission of ASAS, ASAS 5/6 were calculated as well.

Results

7 RCTs were admitted into the meta-analysis, including 186 cases in the control group and 208 cases in the Iguratimod group. The control group was treated with NSAIDs monotherapy or NSAIDs combined with DMARDs, and the range of follow-ups was 12-24 weeks. The improvement of back pain (MD -1.76, 95% CI: -2.33 ~ -1.20, P<0.001), morning stiffness (MD -11.27, 95% CI: -13.57 ~ -8.96, P<0.001), PhGA (MD -2.86, 95% CI: -5.45 ~ -0.26, P<0.05), ASDAS (MD -0.8, 95% CI: -1.26 ~ -0.33, P<0.001), BASDAI (MD -1.19, 95% CI: -1.59 ~ -0.78, P<0.001), BASFI (MD -0.92, 95% CI: -1.29 ~ -0.55, P<0.001), ASAS 20 (OR 11.94, 95% CI: 5.30 ~ 26.91, P<0.001), ASAS 40 (OR 4.46, 95% CI: 1.95 ~ 10.16, P<0.001), partial remission of ASAS (OR 17.69, 95% CI: 4.06 ~ 77.08, P<0.001) in the Iguratimod treatment group were better than those in the control group, as well as for concertation of ESR (MD -8.77, 95% CI: -15.37 ~ -2.18, P<0.001), CRP (MD -4.44, 95% CI: -6.66 ~ -2.23, P<0.001) and TNF-α (MD -6.98, 95% CI: -7.72 ~ -6.24, P<0.01). There was no significant difference in the reported adverse events between the two groups.

Conclusion

Iguratimod is effective and well-tolerated during the treatment and thus could be a new pharmaceutical option for activity ax-SpA patients.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests

None Declared.